Lipid lowering therapy in venous thromboembolism. A Clinical Consensus Statement of the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Cardiovascular Pharmacotherapy, the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, and the European Society of Vascular Medicine (ESVM)

Clicks: 15
ID: 328141
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #236 of 288 articles by views in european journal of preventive cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 288 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The aim of this clinical consensus statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases, the Working Group on Cardiovascular Pharmacotherapy, the Working Group on Pulmonary Circulation & Right Ventricular Function, and the European Society of Vascular Medicine is to summarize existing evidence on lipid-lowering therapy (LLT) in primary and secondary prevention of venous thromboembolism (VTE). VTE, which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), shares common risk factors with atherosclerotic cardiovascular disease (ASCVD). While anticoagulation is the mainstay in the management of patients with VTE, it may be appropriate to define LLT as risk modifier in primary prevention of VTE in populations at high cardiovascular risk. In patients with VTE, assessment of cardiovascular risk factors, including lipid levels, is commonly part of routine cardiovascular care in accordance with existing ESC Guidelines. Finally, this clinical consensus statement highlights the gaps in evidence and the need for large-scale studies directly investigating the role of LLT in secondary prevention of recurrent VTE in high-risk populations.
Reference Key
openalex_W7212016419 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Christine Espinola–Klein, Christian Heiß, Marianne Brodmann, Thomas Gary, Lucia Mazzolai, A. Bura-Rivière, Birgit Linnemann, Victor Aboyans, José F Rodriguez Palomares, Frederikus A Klok, Heinz Drexel, J. J. F. Belch, Mislav Vrsalović, Oliver Schlager
Are you one of these authors? Claim your profile
Journal european journal of preventive cardiology
Year 2026
DOI
10.1093/eurjpc/zwag481
URL
https://academic.oup.com/eurjpc/advance-article-pdf/doi/10.1093/eurjpc/zwag481/71004335/zwag481.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.